Skip to content
OpenCapital
Get started

Beta Bionics, Inc. Common Stock BBNX Q3 2025 earnings

Reported October 28, 2025 · After market close

Revenue$27.3MMiss by $1.7MDiluted EPS-$0.33Beat by $0.12
Revenue estimate$28.9M
EPS estimate-$0.45

Next report

Aug 4, 2026 (in a month)
Revenue estimate$31.5M
EPS estimate-$0.62

Financials

Q3 2025

Income statement

See full
Revenue$27.3M+63.1%
Gross profit$15.1M+69.6%
Operating income-$17.0M-55.3%
Net income-$14.2M-45.9%
EPS (diluted)-$0.33+77.4%

Balance sheet

See full
Cash & equivalents$38.5M+120%
Total debt$7.7M—
Total equity$294.8M+229%
Total assets$330.0M—

Cash flow

See full
Operating cash flow-$8.7M+9.2%
CapEx$1.3M-33.3%
Free cash flow-$10.0M+13.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$863.75M—
Enterprise value$832.95M—
P/S9.8×—

Profitability

See full
Gross margin54.5%+0.5pp
Operating margin-77.4%-7.2pp
Net margin-87.9%-9.5pp
FCF margin-68.3%-14.8pp

Returns & leverage

See full
Debt / equity0×—
Current ratio10.6×—

Segments

By product

See full
I Let$14.2M+28.4%
Single Use Products$6.8M+100%

By geography

See full
Non Us-—

Versus estimates

Revenue

Q1 2026$27.6MBeat by $678.2KQ4 2025$32.1MBeat by $1.7M
Q3 2025$27.3MMiss by $1.7M
Q2 2025$23.2MBeat by $1.3MQ1 2025$17.6MMiss by $2.0MQ4 2024$20.4MBeat by $4.3M

Diluted EPS

Q1 2026-$0.49Beat by $0.04Q4 2025-$0.30Beat by $0.12
Q3 2025-$0.33Beat by $0.12
Q2 2025-$0.39Beat by $0.12Q1 2025-$0.52Miss by $0.01Q4 2024-$1.82Miss by $1.40

Ask the moment Beta Bionics, Inc. Common Stock reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Beta Bionics, Inc. Common Stock report Q3 2025 earnings?
Beta Bionics, Inc. Common Stock (BBNX) reported Q3 2025 earnings on October 28, 2025 after market close.
What were Beta Bionics, Inc. Common Stock's Q3 2025 revenue and EPS?
Beta Bionics, Inc. Common Stock reported revenue of $27.3M and diluted EPS of $-0.33 for Q3 2025.
Did Beta Bionics, Inc. Common Stock beat estimates in Q3 2025?
Revenue missed the consensus estimate of $28.9M by $1.7M. EPS beat the consensus estimate of $-0.45 by $0.12.
How did Beta Bionics, Inc. Common Stock's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 63.1% from $16.7M a year earlier and diluted EPS grew 78.8% from $-1.55.
Where can I find Beta Bionics, Inc. Common Stock's Q3 2025 SEC filings?
You can read the 10-Q periodic report (0001193125-25-253538) directly on SEC EDGAR. The filing index links above go to sec.gov.